A Promising New Therapy of Oral Ixazomib Without Rituximab for Waldenstrom Macroglobulinemia

References (7)

1. Giezen TJ, Mantel-Teeuwisse AK, ten Berg MJ, Straus SM, Leufkens HG, van Solinge WW, Egberts TCG. Rituximab-induced thrombocytopenia: a cohort study. Eur J Haematol 2012;89:256-266
2. Advani P, Paulus A, Ailawadhi S. Updates in prognostication and treatment of Waldenström’s macroglobulinemia. Hematol Oncol Stem Cell Ther 2019;12:179-188
3. Castillo JJ, Meid K, Gustine JN, Dubeau T, Severns P, Hunter ZR, Yang G, Xu L, Treon SP. Prospective clinical trial of ixazomib, dexamethasone and rituximab as primary therapy in Waldenström macroglobulinemia. Clin Cancer Res 2018;24:3247-3252
4. Treon SP, Xu L, Yang G,Zhou Y, Liu X, Cao Y, Sheehy P, Manning RJ, Patterson CJ, Tripsas C, Arcaini L, Pinkus GS, Rodig SJ, Sohani AR, Harris NL, Laramie JM, Skifter DA, Lincoln SE, Hunter ZR. MYD88 L265P somatic mutation in Waldenstrom’s macroglobulinemia. N Engl J Med 2012;367:826-833
5. Dimopoulos MA, Anagnostopoulos A. Waldenström’s macroglobulinemia. Best Pract Res Clin Haematol 2005;18:747-765
6. Vesole DH, Richter J, Biran N, McBride L, Anand P, Huang M, Kumeli AZ, Klippel Z, Iskander K, Siegel DS. Carfilzomib as salvage therapy in Waldenstrom macroglobulinemia: a case series. Leuk Lymphoma 2018;59:259-261
7. Gertz MA, Rue M, Blood E, Kaminer LS, Vesole DH, Greipp PR. Multicenter phase 2 trial of rituximab for Waldenström macroglobulinemia (WM): an Eastern Cooperative Oncology Group Study (E3A98). Leuk Lymphoma 2004;45:2047-2055.